Precision treatment for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests personalized therapies for people with advanced pancreatic cancer that has spread or cannot be removed. It aims to find the best treatment based on your tumor's unique features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- You have advanced pancreatic cancer that has spread or cannot be removed, with at least one tumor that can be measured on scans
- You are in good enough health to be up and about (ECOG score 0 or 1)
- Your major organs (bone marrow, liver, kidneys) are working well enough
- You have not had cancer treatment or major surgery in the past 4 weeks (or 2 weeks for radiation)
- You do not have other active cancers, serious infections, or uncontrolled medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (HRS-4642 and adebrelimab) for people with advanced pancreatic cancer that has not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow the disease.
This trial tests a new drug combined with other treatments for advanced pancreatic cancer. It aims to see if the combination can help people whose cancer has a specific genetic change called RAS mutation.
This trial tests a new drug combination for pancreatic cancer that has not been treated before. It may help shrink tumors or make surgery possible for people with advanced or borderline resectable disease.
This trial tests if giving a combination of four drugs before and after surgery can help treat pancreatic cancer. The drugs include HRS-4642, gemcitabine, nab-paclitaxel, and adebrelimab. It may help shrink the tumor before surgery and lower the chance of cancer coming back afterward.
This study tests a new drug that targets a common genetic change (RAS) in pancreatic cancer, combined with other treatments. It aims to see if this combination is safe and effective for people whose cancer has advanced despite prior therapy.
This trial tests a new kind of immunotherapy for pancreatic cancer that has not been removed by surgery or has spread. It aims to see if the treatment can help shrink or control the cancer, and you may be eligible whether you have had previous chemotherapy or not.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.